These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17497545)

  • 1. Access to drug abuse treatment under Treatment on Demand policy in San Francisco.
    Sorensen JL; Guydish J; Zilavy P; Davis TB; Gleghorn A; Jacoby M; Sears C
    Am J Drug Alcohol Abuse; 2007; 33(2):227-36. PubMed ID: 17497545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug abuse treatment on demand in San Francisco: preliminary findings.
    Guydish J; Moore L; Gleghorn A; Davis T; Sears C; Harcourt J
    J Psychoactive Drugs; 2000; 32(4):363-70. PubMed ID: 11210197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the effects of San Francisco's Treatment on Demand Initiative on a publicly-funded substance abuse treatment system: a time series analysis.
    Sears C; Davis T; Guydish J; Gleghorn A
    J Psychoactive Drugs; 2009 Sep; 41(3):297-304. PubMed ID: 19999683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The San Francisco centralized intake unit: a description of participants and service episodes.
    Woods WJ; Klingemann SD; Guydish JR
    J Psychoactive Drugs; 2002; 34(1):17-24. PubMed ID: 12003109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment on demand: an operational model.
    Kaplan EH; Johri M
    Health Care Manag Sci; 2000 Jun; 3(3):171-83. PubMed ID: 10907320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of California's Proposition 36 on the drug treatment system: treatment capacity and displacement.
    Hser YI; Teruya C; Brown AH; Huang D; Evans E; Anglin MD
    Am J Public Health; 2007 Jan; 97(1):104-9. PubMed ID: 17138930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safe sobering: San Francisco's approach to chronic public inebriation.
    Smith-Bernardin S; Schneidermann M
    J Health Care Poor Underserved; 2012 Aug; 23(3 Suppl):265-70. PubMed ID: 22864503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in access to outpatient substance abuse treatment: organizational factors and conceptual issues.
    McCaughrin WC; Howard DL
    J Subst Abuse; 1996; 8(4):403-15. PubMed ID: 9058353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving access to substance abuse treatment services for consumers with AIDS: a formative evaluation.
    Cooper RL; Cloud R; Besel K; Bennett AJ
    J Evid Based Soc Work; 2010 Jan; 7(1):115-29. PubMed ID: 20178029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.
    Abraham AJ; Knudsen HK; Rieckmann T; Roman PM
    J Stud Alcohol Drugs; 2013 Mar; 74(2):258-65. PubMed ID: 23384373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A field-based dissemination component in a drug abuse research center.
    Sorensen JL; Clark WW
    NIDA Res Monogr; 1995; 155():186-97. PubMed ID: 8594456
    [No Abstract]   [Full Text] [Related]  

  • 13. Operator assistance with process improvement. NIATx helps one agency reduce waiting times from 21 days to 24 hours.
    Fitzgerald M
    Behav Healthc; 2006 May; 26(5):20, 22. PubMed ID: 16736914
    [No Abstract]   [Full Text] [Related]  

  • 14. Bridging the gap in San Francisco: the process of integrating harm reduction and traditional substance abuse services.
    Gleghorn A; Rosenbaum M; Garcia BA
    J Psychoactive Drugs; 2001; 33(1):1-7. PubMed ID: 11332995
    [No Abstract]   [Full Text] [Related]  

  • 15. A note on waiting lists and demand estimation.
    Simeone RS
    Int J Addict; 1993 Aug; 28(10):1033-8. PubMed ID: 8407021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. San Francisco's 'pay or play' employer mandate expanded private coverage by local firms and a public care program.
    Colla CH; Dow WH; Dube A
    Health Aff (Millwood); 2013 Jan; 32(1):69-77. PubMed ID: 23297273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences between U.S. substance abuse treatment facilities that do and do not offer domestic violence services.
    Cohn A; Najavits LM
    Psychiatr Serv; 2014 Apr; 65(4):504-10. PubMed ID: 24430366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accessibility of addiction treatment: results from a national survey of outpatient substance abuse treatment organizations.
    Friedmann PD; Lemon SC; Stein MD; D'Aunno TA
    Health Serv Res; 2003 Jun; 38(3):887-903. PubMed ID: 12822917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alcohol & drug abuse: the transformation of the Veterans Affairs substance abuse treatment system.
    Humphreys K; Huebsch PD; Moos RH; Suchinsky RT
    Psychiatr Serv; 1999 Nov; 50(11):1399-401. PubMed ID: 10543846
    [No Abstract]   [Full Text] [Related]  

  • 20. Deserving to a point: unauthorized immigrants in San Francisco's universal access healthcare model.
    Marrow HB
    Soc Sci Med; 2012 Mar; 74(6):846-54. PubMed ID: 21893374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.